Altasciences Clinical Kansas Inc.
Overland Park, KS Part of Kofile Technologies, Inc.
- UEI
- WZ5RGEMMQ3W9
- CAGE
- 6PS73
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- Corporate family
-
-
Kofile Technologies, Inc.
Parent
GUUCEJ3BYEB4
- Altasciences Clinical Kansas Inc. WZ5RGEMMQ3W9
-
Kofile Technologies, Inc.
Parent
GUUCEJ3BYEB4
- SAM.gov registration date
- Physical address
- 10103 Metcalf Ave, Overland Park, KS 66212, USA
- Website
- altasciences.com
- Founded
- 1992
- Employees
- 1K-5K
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Investigational agent single ascending dose safety, tolerability, and PK study. POP: 5/2/2025 - 11/1/2026. N01DA-23-8935 | National Institute on Drug Abuse | $1,644,109 | |
| Investigational agent single ascending dose safety, tolerability, and PK study. September 3, 2024 to march 2, 2026.… | National Institute on Drug Abuse | $1,724,199 | |
| Pharmacokinetic and pharmacodynamic trials for medication development in SUD. TO1 phase 1 cocaine drug interaction… | National Institute on Drug Abuse | $1,838,615 | |
| Dose-finding study of kratom alkaloids pilot | Food and Drug Administration | $2,370,057 | |
| : pharmacokinetic and pharmacodynamic studies for medications development. POP: 9/20/2017-9/19/2022. N01DA-17-8935. | National Institute on Drug Abuse | $3,562,513 |
About Altasciences Clinical Kansas Inc.
Altasciences Clinical Kansas Inc. is a for-profit contract research organization (CRO) located in Overland Park, Kansas, registered in SAM.gov since 2012. The company specializes in providing advanced clinical research services, particularly in the pharmaceutical and medical research domains, with a strong focus on substance use disorder (SUD) studies and pharmacological research. As a child entity within a larger corporate structure, Altasciences Clinical Kansas Inc. offers comprehensive clinical trial and pharmacological research services to federal agencies, demonstrating expertise in conducting complex medical investigations.
The company has been awarded multiple prime federal contract awards primarily from the National Institute on Drug Abuse (NIDA) and the Food and Drug Administration (FDA), focusing on specialized clinical trials and pharmacological research. These contracts include a $1,838,615 delivery order for Phase 1 cocaine drug interaction trials, a $1,436,776 contract for investigational agent safety and tolerability studies, and a $2,370,057 contract with the FDA for a dose-finding pilot study of kratom alkaloids. None of these contracts were set aside for small businesses, indicating Altasciences Clinical Kansas Inc. competes effectively in the open market. The company's work consistently involves detailed pharmacokinetic and pharmacodynamic trials, demonstrating deep expertise in medication development for substance use disorders.
Altasciences Clinical Kansas Inc. holds a significant single-award indefinite delivery contract (IDV) with NIDA valued at $21 million, which runs from September 25, 2023, to September 24, 2028. This IDV is specifically designed for pharmacokinetic and pharmacodynamic trials supporting medication development in substance use disorders. Under this contract vehicle, the company has already received multiple delivery orders, including trials to assess safety, tolerability, and pharmacokinetics of investigational agents. The IDV allows NIDA to issue task orders for advanced clinical research services, with Altasciences Clinical Kansas Inc. positioned as a key research partner in developing potential treatments for substance use disorders. The contract's broad scope enables the company to conduct various clinical trials and research studies that advance medical understanding and potential therapeutic interventions.
Quick answers
What is Altasciences Clinical Kansas Inc.'s UEI?
Altasciences Clinical Kansas Inc.'s Unique Entity ID (UEI) in SAM.gov is WZ5RGEMMQ3W9.
What is Altasciences Clinical Kansas Inc.'s CAGE code?
Altasciences Clinical Kansas Inc.'s CAGE code is 6PS73.
What is Altasciences Clinical Kansas Inc.'s primary NAICS code?
Altasciences Clinical Kansas Inc.'s primary NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)).
Where is Altasciences Clinical Kansas Inc. located?
Altasciences Clinical Kansas Inc.'s physical address in SAM.gov is 10103 Metcalf Ave, Overland Park, KS 66212, USA.
Is Altasciences Clinical Kansas Inc. registered in SAM.gov?
Yes. Altasciences Clinical Kansas Inc.'s SAM.gov registration is active through June 30, 2027.
Who is Altasciences Clinical Kansas Inc.'s parent company?
Altasciences Clinical Kansas Inc. is part of Kofile Technologies, Inc.
What is Altasciences Clinical Kansas Inc.'s most recent federal award?
Altasciences Clinical Kansas Inc.'s most recent federal contract award is Investigational agent single ascending dose safety, tolerability, and PK study. POP: 5/2/2025 - 11/1/2026. N01DA-23-8935 (75N95025F00001), from National Institute on Drug Abuse, on May 2, 2025.
On GovTribe
See Altasciences Clinical Kansas Inc.'s full federal record
- Federal contract awards
- IDV awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors